Pfizer shuffles its deck post-Seagen
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
T-cell engagers enter new pivotal studies
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
KRAS crowding continues
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Affimed looks to reverse a share price collapse
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
ASH 2023 – Regeneron defends its bispecifics
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
TROP2 gets more crowded
The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.
A trio of new pivotal trial entries
AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.
